Michael Bennett - Concepedia

Author

Michael Bennett

Cincinnati Children's Hospital Medical Center ORCID

Also Known As

Bennett, M.R., Bennett, Michael, F Saeed, H Abdikadir, Larry Berman, M Bennett, M Bennett*, M. BENNETT, M. Bennett, M. R. Bennett

266

Publications

14.5K

Citations

H-Index

198

Concepts

All Affiliations

Cincinnati Children's Hospital Medical Center University of Cincinnati University of California, San Francisco Johns Hopkins University University of California San Diego

About

Michael Bennett is an author at Cincinnati Children's Hospital Medical Center specializing in medicine, nephrology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	56	6.8K
2	Engineering	11	12	265
3	Health Sciences	5	6	1.3K
4	Public Health	3	3	182
5	Natural Sciences	1	1	40

Michael Bennett

129

Publications

12.9K

Citations

H-Index

Page 1

	Year	Citations
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options Ira M. Jacobson, Stuart C. Gordon, Kris V. Kowdley, New England Journal of Medicine	2013	1.1K
Urine NGAL Predicts Severity of Acute Kidney Injury After Cardiac Surgery Michael Bennett, Catherine L. Dent, Qing Ma, Clinical Journal of the American Society of Nephrology	2008	760
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study David R. Nelson, James N. Cooper, Jacob Lalezari, Hepatology	2015	688
Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study Catherine L. Dent, Qing Ma, Sudha Dastrala, Critical Care	2007	481
NGAL is an early predictive biomarker of contrast-induced nephropathy in children Russel Hirsch, Catherine L. Dent, Holly Pfriem, Pediatric Nephrology GlomerulonephritisRenal FunctionContrast-induced NephropathyMedicineKidney Failure	2007	454
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, Journal of Hepatology FibrosisHepatologyLiver PhysiologyClinical TrialsPathology	2020	438
Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery Jay L. Koyner, Michael Bennett, Elaine M. Worcester, Kidney International UrologyRenal FunctionKidney FailureRenal PathologyUrinary Cystatin C	2008	373
Urinary Biomarkers in the Clinical Prognosis and Early Detection of Acute Kidney Injury Jay L. Koyner, Vishal S. Vaidya, Michael Bennett, Clinical Journal of the American Society of Nephrology	2010	360
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease Rohit Loomba, Zeid Kayali, Mazen Noureddin, Gastroenterology ObesityMetabolic SyndromeMetabolic Associated SteatohepatitisHepatologyMetabolic Associated Steatotic Liver Disease	2018	329

Page 1